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OBJECTIVES The goal of this study was to investigate the effect of three different doses of acetylsalicylic
acid (aspirin) (ASA) on the late phase of ischemic preconditioning (PC) against myocardial
stunning.
BACKGROUND Although recent evidence indicates that the late phase of ischemic PC is mediated by
cyclooxygenase-2 (COX-2), the effect of nonsteroidal anti-inflammatory drugs (NSAIDs)
that inhibit COX-2 activity on late PC has not been evaluated; ASA is the most widely used
NSAID. Therefore, we determined whether ASA impedes the development of late PC.
METHODS Conscious rabbits underwent a protocol consisting of three days of six 4-min coronary
occlusion/4-min reperfusion cycles.
RESULTS Neither 5 mg/kg nor 10 mg/kg  3 of ASA interfered with the protective effects of late PC
against stunning. In contrast, the late PC effect was completely abrogated by 25 mg/kg of
ASA. Low-dose (5 mg/kg) ASA effectively inhibited platelet aggregation but did not prevent
the increase in COX-2 activity, whereas the highest dose (25 mg/kg) completely blocked
COX-2 activity.
CONCLUSIONS The administration of ASA either at antithrombotic doses (5 mg/kg), which are widely used
to prevent cardiovascular events in patients, or at analgesic/antipyretic doses (10 mg/kg) does
not interfere with the cardioprotective effects of late PC against myocardial stunning. In
contrast, high doses of ASA (25 mg/kg), which are used as antirheumatic therapy, abrogate
both COX-2 activity and late PC, suggesting that nonselective doses of NSAIDs should be
used with caution in patients with atherosclerotic cardiovascular disease because they may
deprive the heart of its innate defensive response. (J Am Coll Cardiol 2003;41:1183–94)
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The late phase of ischemic preconditioning (PC) is an
innate response to stress that renders the heart relatively
resistant to ischemia/reperfusion injury (1). The develop-
ment of powerful protection against myocardial stunning is
one of the most consistent aspects of late PC (1–3). Recent
evidence has shown that the inducible isoform of cycloox-
ygenase (COX), COX-2, plays an essential role in mediat-
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ing the cardioprotective effects of late PC (3–6). In the
myocardium, COX-2 is normally expressed at low levels but
is upregulated after ischemic PC leading to increased
synthesis of prostaglandin (PG)E2 and PGI2 (3,6); COX-
2–dependent production of these prostanoids protects
against ischemia/reperfusion injury during the late phase of
ischemic PC (3–6).
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit
COX-1 and COX-2 activity and are widely used clinically.
Acetylsalicylic acid (aspirin) (ASA) is the most commonly
used NSAID for relieving pain, inflammatory symptoms,
and fever (7). In addition, ASA has established efficacy for
preventing cardiovascular events (7–9) and is prescribed
almost universally to patients with coronary artery disease.
Mounting evidence indicates that both ischemic and phar-
macological PC occurs in these patients (10–14) and results
in significant clinical benefits. If the mechanism involved in
the development of ischemic PC in humans is similar to
that in animals, an important question arises as to whether
the use of ASA might affect the development of late PC.
Relatively low doses (75 to 325 mg/day) of ASA are
currently recommended for the prophylaxis of cardiac and
cerebral ischemic events and, as mentioned above, are given
to almost all patients with coronary artery disease (7). The
ability of these doses of ASA to inhibit COX-1 activity is
well established (7,15), but it is unknown whether these
doses can also interfere with the cardioprotective effects of
late PC by inhibiting COX-2 as well. In addition, it is
unknown whether late PC is affected by higher doses of
ASA, which are commonly used to treat fever, pain, and
inflammatory states. The importance of examining the
impact of COX inhibitors on myocardial ischemia is em-
phasized by the results of the Vioxx Gastrointestinal Out-
comes Research (VIGOR) trial (16), in which the rate of
myocardial infarction was four times higher among patients
treated with the selective COX-2 inhibitor rofecoxib as
compared with patients treated with naproxen, a nonselec-
tive COX inhibitor. A recent meta-analysis has concluded
that inhibition of COX-2 increases the incidence of cardio-
vascular events in patients with coronary artery disease (17).
From the Experimental Research Laboratory, Division of Cardiology, University of
Louisville, and the Jewish Hospital Heart and Lung Institute, Louisville, Kentucky.
Supported, in part, by NIH grants R01 HL-43151, HL-55757, and HL-68088 to
Dr. Bolli, and HL-65660 to Dr. Xuan.
Manuscript received August 14, 2002; revised manuscript received November 8,
2002, accepted November 22, 2002.
Journal of the American College of Cardiology Vol. 41, No. 7, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. doi:10.1016/S0735-1097(03)00086-X
Accordingly, the aim of this study was to investigate the
effect of three different doses of ASA on the late phase of
ischemic PC in rabbits. All studies were conducted in
conscious animals to obviate the potential confounding
influence of conditions associated with open-chest animal
preparations (18), particularly since COX-2 is known to be
a stress-responsive enzyme (19).
METHODS
The conscious rabbit model of myocardial ischemia has
been described in detail previously (2,3).
Experimental protocols. PROTOCOL I: EFFECT OF ASA ON
LATE PC AGAINST MYOCARDIAL STUNNING. In this proto-
col, rabbits underwent three consecutive days of six 4-min
coronary occlusion/4-min reperfusion cycles (Fig. 1). Group
I (untreated control) underwent the coronary artery occlu-
sion/reperfusion protocol on days 1, 2, and 3 without any
treatment. In group II (low ASA on day 2), rabbits
underwent six 4-min coronary occlusion/4-min reperfusion
cycles without any treatment on day 1. On day 2, rabbits
received low-dose ASA (5 mg/kg) through a nasogastric
tube 40 min before the first occlusion, whereas on day 3,
rabbits underwent the six occlusion/reperfusion cycles with-
out any treatment. In group III (high ASA on day 1),
rabbits received high-dose ASA (25 mg/kg) via a nasogas-
tric tube 40 min before the first occlusion on day 1. On days
2 and 3, rabbits underwent the six coronary occlusion/
reperfusion cycles without any treatment. In group IV (high
ASA on day 2), rabbits underwent the six occlusion/
reperfusion cycles without any treatment on day 1. On day
2, they received 25 mg/kg of ASA 40 min before the first
occlusion, and on day 3, they underwent six occlusion/
Abbreviations and Acronyms
ASA  acetylsalicylic acid (aspirin)
COX  cyclooxygenase
NSAID(s)  nonsteroidal anti-inflammatory drug(s)
PC  preconditioning
PG  prostaglandin
WTh  systolic wall thickening
Figure 1. Experimental protocols (protocol I): effect of acetylsalicylic acid (aspirin [ASA]) on late preconditioning (PC) against myocardial stunning. O 
occlusion; R  reperfusion.
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reperfusion cycles without any treatment. In group V
(multiple ASA), rabbits underwent the six occlusion/
reperfusion cycles on day 1 and then received three doses of
ASA (10 mg/kg each) every 12 h (30 min and 12 h after the
sixth reperfusion on day 1 and 40 min before the first
occlusion on day 2; total cumulative dose: 30 mg/kg over
24 h). On day 3, they underwent six occlusion/reperfusion
cycles without any treatment; ASA was administered in
10 ml of water using a nasogastric tube, with another 10 ml
of water to flush the tube (total of 20 ml of water).
PROTOCOL II: EFFECT OF ASA ON PLATELET FUNCTION. To
evaluate the efficacy of ASA in inhibiting platelet function,
blood samples were collected before and after the adminis-
tration of ASA in group VI (low ASA) (weight: 3.0 to
3.5 kg) (Fig. 2). Ten milliliters of blood were drawn from
the mid-dorsal ear artery into a syringe containing sodium
citrate (final concentration 3.8%) before and 60 min after
the administration of low-dose ASA (5 mg/kg) via a
nasogastric tube. Platelet function in citrated whole blood
samples was analyzed by a platelet function analyzer
(PFA-100, Dade Behring, Inc., Deerfield, Illinois) (20)
according to the manufacturer’s protocol. After determina-
tion of circulating blood cell counts, platelet function was
assessed using simulated blood flow in presence of epineph-
rine/collagen or adenosine diphosphate/collagen agonists.
Figure 2. Experimental protocols (protocols II and III): effect of acetylsalicylic acid (aspirin [ASA]) on platelet function. COX  cyclooxygenase; O 
occlusion; R  reperfusion.
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PROTOCOL III: EFFECT OF ASA ON COX-2 PROTEIN EXPRES-
SION AND ACTIVITY. As shown in Figure 2, group VII
(control) did not receive any treatment or ischemic PC. In
groups VIII (PC), IX (high ASA on day 1), X (low ASA on
day 2), and XI (high ASA on day 2), rabbits underwent six
cycles of 4-min occlusion/4-min reperfusion without ASA
on day 1. In group IX (high ASA on day 1), rabbits received
high-dose ASA (25 mg/kg) 40 min before the first occlu-
sion on day 1. In groups X and XI, rabbits received low-dose
(5 mg/kg) or high-dose (25 mg/kg) ASA 40 min before
euthanasia on day 2. Twenty-four hours later (on day 2),
myocardial samples were obtained from the ischemic-
reperfused and nonischemic region (posterior left ventricu-
lar wall) and stored at 140°C until used.
Measurements. Regional myocardial function was assessed
as systolic thickening fraction using a Doppler probe (21).
The total deficit of systolic wall thickening (WTh) (an inte-
grative assessment of the overall severity of postischemic
dysfunction) was calculated as described (2,3). The expression
of COX-2 was assessed by standard sodium dodecyl sulfate-
polyacrylamide gel electrophoresis Western immunoblotting
techniques using monoclonal anti-COX-2 antibodies (Trans-
duction Laboratories, Lexington, Kentucky) (3,6). The myo-
cardial content of PGE2 and 6-keto-PGF1 was determined
using enzyme immunoassay kits as described (3,6).
Statistical analysis. Data are reported as means  SEM.
For intragroup comparisons, hemodynamic variables and
WTh were analyzed by a one-way analysis of variance,
followed by Student t tests for paired data with the
Bonferroni correction. For intergroup comparisons, data
were analyzed by either a one-way or a two-way repeated
measures analysis of variance (time and group), as appro-
priate, followed by Student t tests for unpaired data with the
Bonferroni correction.
RESULTS
Exclusions. A total of 73 rabbits were used. Of the 40
rabbits instrumented for protocol I (studies of myocardial
stunning), three were excluded because the WTh signal was
lost on day 2 (one each in groups II, IV, and V), and two
died of ventricular fibrillation during the coronary occlusion
on day 2 (one each in groups II and III). Thus, seven rabbits
completed the study in group I, seven in group II, eight in
group III, eight in group IV, and five in group V. Of the
eight rabbits assigned to protocol II (platelet function),
three were excluded because of difficulty in obtaining blood
samples for the analysis of platelet function after the
administration of ASA; thus, five rabbits completed proto-
col II. All of the 25 rabbits assigned to protocol III (COX-2
expression and activity) completed the study.
PROTOCOL I: EFFECT OF ASA ON LATE PC AGAINST MYO-
CARDIAL STUNNING. There were no appreciable differences
in heart rate throughout the experimental protocol among
the five groups (Table 1). There were also no differences in
thickening fraction at baseline and just before coronary
occlusion (Table 2). As shown in Table 3, the left ventricular
weight and the size of the occluded-reperfused vascular bed
(area-at-risk) did not differ significantly among the five groups.
As expected (2,3), in control rabbits (group I), the
recovery of WTh during the 5-h reperfusion period was
improved on days 2 and 3 compared with day 1 (Fig. 3),
resulting in a significant decrease in the total deficit of WTh
after the sixth reperfusion on days 2 and 3, respectively,
compared with day 1 (p  0.05 for both) (Fig. 4). This
indicates the development of late PC against stunning.
Similar results were obtained in rabbits given low-dose ASA
on day 2 (group II) (Figs. 4 and 5A). Thus, 5 mg/kg of ASA
given on day 2 did not abrogate late PC against stunning.
In group III (high ASA on day 1), the total deficit of
WTh on day 1 did not differ from that measured on day 1
in groups I, II, IV, and V (p 0.46) (Fig. 4), demonstrating
that the administration of high-dose ASA (25 mg/kg) did
not affect the severity of myocardial stunning in nonprecon-
ditioned myocardium. These results are consistent with
previous reports in vivo (22) and suggest that, in the absence
of a PC stimulus, endogenous biosynthesis of prostanoids
does not modulate the severity of myocardial stunning. On
days 2 and 3, the recovery of WTh was significantly improved
compared with day 1 (Fig. 5B), and the total deficit of WTh
was significantly decreased (Fig. 4), indicating that a single
high dose of ASA (25 mg/kg) given on day 1 did not block the
development of late PC against stunning on day 2.
In group IV (high ASA on day 2), the recovery of WTh
on day 2 was essentially indistinguishable from that on day
1 (Fig. 6A), and the total deficit of WTh was similar to that
on day 1 (Fig. 4), indicating that the administration of
high-dose (25 mg/kg) ASA on day 2 completely abrogated
late PC against stunning. On day 3, the recovery of WTh was
significantly improved (Fig. 6A), and the total deficit of WTh
was attenuated to the same extent as in groups I, II, III, and V
(Fig. 4), indicating a late PC effect against stunning.
In group V (multiple ASA), the total deficit of WTh on
day 1 was similar to that measured on day 1 in groups I, II,
III, and IV (Fig. 4). On days 2 and 3, the recovery of WTh
was significantly improved compared with day 1 (Fig. 6B),
resulting in a marked decrease in the total deficit of WTh
versus day 1 (Fig. 4). Therefore, administration of multiple
doses of ASA (10 mg/kg  3) during the 24-h interval
before the six occlusion/reperfusion cycles on day 2 did not
block the development of late PC against stunning on day 2.
PROTOCOL II: EFFECT OF ASA ON PLATELET FUNCTION. In
the five rabbits studied in group VI (low ASA), there were
no significant differences in the number of white blood cells
and platelets before and after the administration of ASA.
The number of red blood cells decreased slightly but
significantly after ASA administration, probably due to the
previous blood sampling (Table 4). Platelet aggregation in
response to epinephrine/collagen was suppressed by low-
dose (5 mg/kg) ASA; in contrast, platelet aggregation in
response to ADP/collagen was unchanged after ASA (Table
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O1 O3 O6 R15 R30 R1h R2h R3h R4h R5h
Group I (control)
Day 1 — 230  9 241  7 251  7 241  6 237  11 237  6 230  9 238  7 230  10 224  6 228  8
Day 2 — 239  7 254  6 249  9 247  5 245  8 238  10 242  8 238  8 225  8 238  8 238  8
Day 3 — 245  14 257  9 255  9 246  5 231  11 245  9 241  9 244  9 233  11 233  9 225  8
Group II (low ASA on day 2)
Day 1 — 262  10 265  11 244  8 235  10 235  6 243  9 257  13 240  11 239  11 235  11 231  13
Day 2 255  6 260  12 262  11 247  9 247  13 244  11 240  13 231  10 237  11 231  10 237  12 235  12
Day 3 — 256  5 266  13 261  10 252  12 236  7 226  8 230  5 221  8 219  12 215  7 220  10
Group III (high ASA on day 1)
Day 1 247  5 234  8 258  10 247  10 243  4 227  10 236  9 232  10 229  9 232  13 223  10 221  12
Day 2 — 239  9 259  9 244  7 244  7 229  12 234  18 230  14 234  11 235  13 224  10 211  7
Day 3 — 244  6 249  6 244  11 245  8 241  14 232  11 239  9 237  13 236  17 213  10 227  15
Group IV (high ASA on day 2)
Day 1 — 220  8 246  9 253  7 236  11 214  8 218  7 210  7 221  5 207  5 210  9 202  5
Day 2 244  12 233  13 246  11 253  9 244  12 232  13 223  12 223  10 228  17 236  15 229  14 225  14
Day 3 — 236  9 244  8 236  7 232  7 229  6 218  14 220  13 221  13 211  17 219  15 224  12
Group V (multiple ASA)
Day 1 — 274  9 267  10 256  10 251  8 242  5 246  5 267  9 274  14 270  7 250  6 254  8
Day 2 272  13 255  8 257  11 240  10 238  9 242  8 246  13 259  14 252  9 262  14 241  7 242  8
Day 3 — 255  8 258  14 244  9 243  6 247  9 241  8 230  4 232  9 246  13 255  7 238  8
Values are means  SEM. ASA  acetylsalicylic acid; Baseline  before the administration of ASA; Before occlusion  just before coronary occlusion; O1  1st occlusion; O3  3rd occlusion; O6  6th occlusion; R15  15 min
















4). Thus, the inhibitory effect of ASA (5 mg/kg) on platelet
aggregation in rabbits is similar to the effect of low-dose
ASA in humans (7,20).
PROTOCOL III: EFFECT OF ASA ON COX-2 PROTEIN EXPRES-
SION AND ACTIVITY. Representative examples of Western
immunoblotting analysis of COX-2 in membranous frac-
tions are illustrated in Figure 7. A weak COX-2 signal
was detected in control hearts (group VII). When rabbits
were preconditioned with six 4-min occlusion/4-min reper-
fusion cycles (group VIII), the expression of COX-2 in the
ischemic-reperfused region increased markedly 24 h later
(Fig. 7, left panel), in keeping with our previous obser-
vations (3,6). The administration of high-dose ASA
(25 mg/kg) before ischemic PC failed to abolish the
upregulation of COX-2 protein 24 h later (group IX)
(Fig. 7, left panel). There was no change in COX-2 protein
expression in the nonischemic region among the three
groups (Fig. 7, right panel).
Previous studies in this conscious rabbit model have
demonstrated that the two main products of enhanced
COX-2 activity during late PC are PGE2 and 6-keto-
PGF1 (the stable metabolite of PGI2) (3,6). Consistent
with these prior studies, we found that ischemic PC (group
VIII) resulted in a significant increase in both PGE2 and
6-keto-PGF1 levels in the ischemic region 24 h later
(Fig. 8). The myocardial levels of PGE2 and 6-keto-PGF1
were lower in groups IX (high ASA on day 1) and X (low
ASA on day 2) than in group VIII (PC), indicating that
administration of high-dose ASA on day 1 or low-dose
ASA on day 2 produced partial inhibition of COX-2
activity; nevertheless, PGE2 and 6-keto-PGF1 were sig-
nificantly higher in groups IX and X than in group VII
(controls), indicating that COX-2 activity was still upregu-
lated in these two groups (Fig. 8). In contrast, in group XI
(high ASA on day 2) the myocardial levels of PGE2 and
6-keto-PGF1 were indistinguishable from controls (Fig.
8), indicating that the enhanced COX-2 activity induced by
ischemic PC was completely abrogated by the administra-
tion of high-dose ASA on day 2.
DISCUSSION
The late phase of PC plays an important role in enhancing
the tolerance of the heart to stress (1). To our knowledge,
this is the first report to evaluate the effect on late PC of
ASA, an NSAID that is widely used to prevent cardiovas-
cular events. The present study provides three major find-
ings: 1) the administration of a low dose of ASA (5 mg/kg),
which is sufficient to inhibit platelet aggregation, does not
prevent the increase in COX-2 activity and does not ablate
the cardioprotective effects of late PC; 2) multiple higher
doses of ASA, in the range used for analgesic/antipyretic
effects (10 mg/kg  3 over 24 h), also do not block late PC;
and 3) in contrast, a very high dose of ASA, in the range
used for antirheumatic therapy (25 mg/kg), abrogates
COX-2 activity and the cardioprotection afforded by late
PC. These results suggest that, in patients taking NSAIDs,
the ability of the myocardium to shift to a preconditioned
phenotype is not impaired so long as these drugs are given
in doses that are selective for COX-1; however, doses of
NSAIDs that completely block COX-2 can deprive the
heart of its innate defensive response.
Effect of escalating doses of ASA on late PC. In clinical
practice, ASA is used at three different dosage levels, with
each dose reflecting the relative ASA sensitivity of different
target cells (7); ASA acts as an antithrombotic (60 to
325 mg per day), as an analgesic/antipyretic (650 mg), or as
an antirheumatic agent (3,000 to 6,000 mg). We chose
Table 2. Thickening Fraction (%) on Each Experimental Day
Baseline Before Occlusion
Group I (control)
Day 1 — 33.9  1.3
Day 2 — 32.4  1.3
Day 3 — 32.4  1.3
Group II (low ASA on day 2)
Day 1 — 34.9  3.1
Day 2 32.6  2.5 33.0  2.7
Day 3 — 33.2  2.5
Group III (high ASA on day 1)
Day 1 38.0  2.8 36.7  3.2
Day 2 — 35.4  2.8
Day 3 — 35.8  3.1
Group IV (high ASA on day 2)
Day 1 — 30.5  1.7
Day 2 29.7  1.6 31.3  1.8
Day 3 — 31.4  1.6
Group V (multiple ASA)
Day 1 — 28.6  2.2
Day 2 27.8  2.6 28.5  2.2
Day 3 — 27.4  1.9
Values are means  SEM.
ASA  acetylsalicylic acid; Baseline  before the administration of ASA; Before
occlusion  just before coronary occlusion.
Table 3. Size of Occluded-Reperfused Vascular Bed (Region-at-Risk)
Number LV (g) Region-at-Risk (g)
Region-at-Risk
(% of LV)
Group I (control) 7 4.21  0.17 0.84  0.09 20.3  1.7
Group II (low ASA on day 2) 7 3.80  0.33 0.76  0.11 20.6  3.5
Group III (high ASA on day 1) 8 3.84  0.20 0.81  0.11 21.2  2.9
Group IV (high ASA on day 2) 8 4.27  0.21 1.06  0.09 25.5  2.6
Group V (multiple ASA) 5 4.15  0.16 0.84  0.12 20.1  2.8
Values are means  SEM.
ASA  acetylsalicylic acid; LV  left ventricle.
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Figure 3. Systolic thickening fraction in group I (control). Illustrated is thickening fraction at baseline, just before the first occlusion (Pre-O), 3 min into
each coronary occlusion (O), 3 min into each reperfusion (R), and at selected times during the 5-h reperfusion period after the sixth occlusion. Thickening
fraction is expressed as a percentage of baseline values. The two comparisons performed at each time-point from 5 min to 4 h of reperfusion were adjusted
with the Bonferroni correction. Data are means  SEM.
Figure 4. Total deficit of systolic wall thickening after the sixth reperfusion. The total deficit of systolic wall thickening was measured in arbitrary units,
as described in the text. The two comparisons performed in each group were adjusted by the Bonferroni correction. Data are means  SEM. ASA 
acetylsalicylic acid.
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Figure 5. Systolic thickening fraction in group II (low acetylsalicylic acid [aspirin {ASA}] on day 2) (A) and in group III (high ASA on day 1) (B). Same
format as Figure 3. In both groups II and III, the two comparisons performed at each time-point from 5 min to 4 h of reperfusion were adjusted with the
Bonferroni correction. Data are means  SEM. Pre-O  before first occlusion; O/R  occlusion/reperfusion.
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Figure 6. Systolic thickening fraction in group IV (high acetylsalicylic acid [aspirin {ASA}] on day 2) (A) and in group V (multiple ASA) (B). Same format
as Figure 3. In both groups IV and V, the two comparisons performed at each time-point from 5 min to 4 h of reperfusion were adjusted with the Bonferroni
correction. Data are means  SEM. Pre-O  before first occlusion; O/R  occlusion/reperfusion.
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5 mg/kg as the low dose because this dosage is comparable
to that used to prevent cardiovascular events in patients (7).
We found that this dose of ASA inhibited platelet aggre-
gation (a COX-1-dependent phenomenon) (Table 4) but
had no effect on late PC against stunning (a COX-2-
dependent phenomenon) (Figs. 4 and 5A) and did not
prevent the increase in cardiac COX-2 activity (although it
exerted a partial inhibition) (Fig. 8). We also evaluated a
dosage of aspirin that is commonly used for its analgesic/
antipyretic effects (10 mg/kg every 12 h). Even after three doses
(total cumulative dose of 30 mg/kg over 24 h), late PC against
stunning was not blocked (Figs. 4 and 6B). Taken together,
these results indicate that doses of ASA commonly given to
patients (5 to 10 mg/kg) do not interfere with late PC.
Table 4. Complete Blood Count and Platelet Function Before and After ASA in Five Rabbits
Baseline After ASA (5 mg/kg per os)
Units p ValueComplete Blood Count
White blood cells 7.3  0.5 7.0  0.4 103/ml NS
Red blood cells 5.52  0.06 5.19  0.06 106/ml p  0.05
Hemoglobin 12.0  0.4 11.5  0.4 g/dl NS
Hematocrit 35.4  0.8 34.1  1.1 % NS
Platelets 231  22 217  23 103/ml NS
Platelet Aggregation Tests
Epinephrine/collagen 124  15 212  16 s p  0.05
ADP/collagen 108  8 103  8 s NS
Values are means  SEM.
ADP  adenosine diphosphate; ASA  acetylsalicylic acid.
Figure 7. (Upper panel) Representative Western immunoblots showing the expression of cyclooxygenase (COX-2) protein in the membranous fraction in
the ischemic/reperfused region. (Lower panels) Densitometic analysis of COX-2 protein signals in the membranous fraction in the ischemic/reperfused
region (anterior left ventricular [LV] wall) (left) and in the nonischemic region (posterior LV wall) (right). In all samples, the densitometric measurements
of COX-2 immunoreactivity were expressed as a percentage of the average value measured in the corresponding LV wall of control rabbits. The two comparisons
performed in each panel were adjusted by the Bonferroni correction. Data are means  SEM. ASA  acetylsalicylic acid (aspirin); PC  preconditioning.
1192 Shinmura et al. JACC Vol. 41, No. 7, 2003
Effect of Aspirin on Late PC April 2, 2003:1183–94
The ability of ASA to prevent platelet aggregation and,
thereby, prevent cardiac and cerebral ischemia, results from
inhibition of COX-1 due to irreversible acetylation of the
protein at serine 530 (7,15); ASA also inhibits COX-2 in a
similar manner but exhibits less potency for COX-2 than
for COX-1 (23) because the substrate channel of COX-2 is
larger and more flexible than that of COX-1 (24). These
considerations provide a plausible explanation for our find-
ing that 5 mg/kg and 10 mg/kg of ASA inhibited platelet
aggregation but failed to affect late PC.
In contrast with the effects of antithrombotic and anal-
gesic/antipyretic doses of ASA, administration of an anti-
rheumatic dose of ASA (25 mg/kg) completely ablated the
beneficial actions of late PC on myocardial stunning (Figs.
4 and 6A) and the attending increase in COX-2 activity
(Fig. 8), indicating loss of COX-1 selectivity. Interestingly,
although this dose of ASA (25 mg/kg) blocked the benefi-
cial effects of late PC on day 2, it failed to exacerbate
postischemic dysfunction on day 1 in nonpreconditioned
hearts (Figs. 4 and 5A), indicating that endogenous biosyn-
thesis of prostanoids does not modulate the severity of
myocardial stunning in the absence of a PC stimulus. This
finding reveals a heretofore unrecognized difference in the
response of the myocardium to COX inhibitors; that is,
inhibition of COX-2 (or COX-1) activity has no effect in
the unstressed (nonpreconditioned) state, where COX-2 is
not upregulated, but exacerbates ischemia/reperfusion injury
in the stressed (preconditioned) state, where COX-2 is
upregulated.
Effect of ASA on COX-2 protein induction. The impe-
tus to examine the effect of high-dose ASA on COX-2
induction in protocol III was provided by the recent
demonstration that, besides inhibiting COX activity,
some NSAIDs can also suppress the transcription of
inflammation-related genes via inhibition of transcriptional
activators (25). Among these, nuclear factor-kappaB plays a
major role in controlling the transcription of the COX-2
gene (26) and also in the development of the late PC
phenotype (1). In noncardiac cells studied in vitro, ASA has
been found to inhibit nuclear factor-kappaB activation
(27,28), and Xu et al. (9) have reported that it blocks
COX-2 transcription. In the present study, however, nei-
ther the induction of COX-2 protein (Fig. 7) nor the
development of a late PC effect 24 h later (on day 2) (Figs.
4 and 5B) was affected by the administration of 25 mg/kg of
ASA on day 1 (before ischemic PC), demonstrating that
even very high doses of ASA fail to block upregulation of
COX-2 in response to a sublethal ischemic stress in the
heart. There are several possible explanations for the appar-
ent discrepancy between our results and those of Xu et al.
(9). Aside from the obvious differences in experimental
models (in vivo vs. in vitro), stimuli for COX-2 induction
(ischemia vs. nonischemic stimuli), and cell types examined
(cardiac tissue vs. noncardiac cells), it is plausible that
multiple transcription factors are involved in the induction
of cardiac COX-2 after ischemic PC (1), so that inhibition
of one factor might not suffice to suppress COX-2 gene
transcription in this setting.
Our measurements of tissue prostanoid levels (Fig. 8)
Figure 8. Myocardial levels of prostaglandin (PG)E2 and 6-keto-PGF1 (measured by enzyme immunoassay). The three intergroup comparisons performed
in each panel were adjusted by the Bonferroni correction. Data are means  SEM. ASA  acetylsalicylic acid (aspirin); PC  preconditioning.
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demonstrate that COX-2 activity was partially inhibited by
5 mg/kg of ASA given on day 2 and 25 mg/kg of ASA given
on day 1. In the former case, this most likely reflects the
limited selectivity of ASA for COX-1 vis-a`-vis COX-2
(8,23). In the latter case, it may reflect irreversible inhibition
of constitutive or induced COX-2 protein that was present
in the heart in the first few hours after administration of
ASA on day 1. The fact that in both cases the late PC
response was intact indicates that the upregulation of
COX-2 during late PC is somewhat redundant; that is,
COX-2-dependent biosynthesis of prostanoids is sufficient
to confer cardioprotection even when it is partially inhib-
ited, implying that complete blockade of COX-2 activity is
necessary to block late PC.
Conclusions and clinical implications. In summary, using
a conscious animal model, we found that administration of
ASA either at antithrombotic doses (5 mg/kg), which are
widely used to prevent cardiovascular events in patients, or
at analgesic/antipyretic doses (10 mg/kg) does not interfere
with the cardioprotective effects of late PC against myocar-
dial stunning. In contrast, high doses of ASA (25 mg/kg),
which are used as antirheumatic therapy, abrogate COX-2
activity as well as late PC, suggesting that they should be
used with caution in patients with atherosclerotic cardiovas-
cular disease because they may deprive the heart of its innate
defensive response. Given the ubiquitous use of ASA and
other NSAIDs and the increasing use of selective COX-2
inhibitors, the present findings have potential clinical rever-
berations. Recent studies indicate that COX-2 inhibitors
increase the incidence of cardiovascular events (16,17),
possibly because they inhibit late PC (a COX-2-dependent
phenomenon) without inhibiting platelet aggregation (a
COX-1-dependent phenomenon) (4). Because many
NSAIDs, such as ibuprofen and indomethacin, are less
COX-1 selective than ASA (8), they may interfere with late
PC at relatively lower doses. Our results suggest that the
actions of NSAIDs in patients with atherosclerosis are more
complex than heretofore appreciated, and that when
NSAIDs are given in doses sufficient to block COX-2,
inhibitions of the PC response may offset the benefits
deriving from inhibition of platelet aggregation.
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